Research and Markets (http://www.researchandmarkets.com/research/1220f8/e7_the_outlook_fo) has announced the addition of the "E7: The Outlook for Pharmaceuticals to 2012" report to their offering.
E7: The Outlook for Pharmaceuticals to 2012 is a new collection of management reports. This report provides an individual and highly-detailed analysis of each market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually or as a discounted collection.
Highlights from the report:
BRAZIL
Due to the depreciation of the US dollar, the Brazilian pharmaceutical market is experiencing high growth in dollar values. The Brazilian pharmacy sector was valued at US$9.8 billion in 2006, ahead of the pharmacy sector in Mexico, valued at US$9.6 billion. Drug prices continue to increase in spite of generic competition. The generics sector is dominated by local producers, restricting the market entry for foreign producers. In 2006, generics sales amounted to US$1.1 billion, equal to 10.7% of the overall pharmacy sector. Generics sales will continue to outperform the pharmacy sector, fuelled by generics production of oral contraceptives & hormones and blockbusters losing their patents.
CHINA
The Chinese pharmaceutical market has shown impressive growth in recent years, in tandem with the country's rapid economic expansion. The influx of foreign multinationals in recent years has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies. The market is heavily reliant on locally-produced generics or copy products. Intellectual property provision is theoretically strong; China became a WTO member in 2001. However, enforcement remains a major issue, with courts tending to favour local producers.
INDIA
With a population of over one billion and a significant middle class capable of paying for advanced medicines, the pharmaceutical market in India has enormous potential and Espicom projects sustainable market growth of around 8.4% per year, putting the market at US$15.6 billion by 2012. It should be noted, however, that if calls for an end to drug price controls come to fruition, short-term market growth is likely to be much higher. Even allowing for liberalisation, prices are unlikely to soar with the advent of product patent recognition. The government will retain the power to intervene in cases where prices are considered high in order to protect the interests of the poorer sections of society. Also, the market will remain dominated by generics for the foreseeable future and fierce price competition in this sector will remain. The gradual introduction of new, proprietary medicines is unlikely to have a significant effect on the overall value of the market.
INDONESIA